Skip to content

Crescent Biopharma

US · CBIO #3749 by market cap
13.00 +0.09 +0.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 12.56 -2.71%
After-hours 13.00 0.00%
21.4711.8413.002026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CBIO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -10.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 11.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -1,407.5% Better than 2%
Net margin -1,419.6% Better than 2%
Return on equity -167.8% Better than 3%
Return on invested capital -138.5% Better than 1%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -24.2% Better than 24%
6-month return -37.3% Better than 14%
12-month return (ex latest month) -1.8% Better than 32%
Distance below 52-week high 52.6% Better than 17%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.6x Better than 90%
Debt to assets 0.7% Better than 95%
Interest coverage -68.5x Better than 6%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 146.2% Better than 90%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.13%
1M -0.54%
3M -19.90%
6M -31.25%
YTD +9.61%
1Y -0.61%
3Y -91.50%

Key statistics

Price & volume

Prev close
12.91
Open
12.55
Day range
12.53 - 13.30
Avg price
12.98
Volume
422.37K
Turnover
5.48M
Amplitude
5.95%
52-week range
8.72 - 27.41

Valuation

P/E
-1.01
P/E (TTM)
-1.78
P/B
1.87
EPS
-12.81
Net profit
-498.25M
Net assets
270.28M

Share structure

Market cap
505.64M
Float cap
219.61M
Shares out
38.90M
Float shares
16.89M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 23% of range
8.72 27.41

52.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-3.10M net over the window

Short interest

Shares short
4.16M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Crescent Biopharma (CBIO)?

Crescent Biopharma last traded at 13.00. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Crescent Biopharma's market cap?

About 505.64M.

What is the P/E ratio of Crescent Biopharma?

The trailing twelve-month P/E is -1.78. The Valuation tab shows it against the stock's own five-year range.

Does Crescent Biopharma pay a dividend?

Crescent Biopharma does not currently pay a regular dividend.

Is Crescent Biopharma a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 32.00, which implies 146.2% upside from the current price. This is not investment advice.

What is Crescent Biopharma's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Crescent Biopharma a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Crescent Biopharma discussion 0 comments

Add a comment